Evaluation and Prognostic Significance of Circulating Tumor Cells in Patients With Non–Small-Cell Lung Cancer
| العنوان: | Evaluation and Prognostic Significance of Circulating Tumor Cells in Patients With Non–Small-Cell Lung Cancer |
|---|---|
| المؤلفون: | Roberta Ferraldeschi, Lee Lancashire, Lynsey Priest, Timothy H Ward, Alastair Greystoke, Fiona H Blackhall, Jian-Mei Hou, Matthew G Krebs, Glen Clack, Andrew Hughes, Caroline Dive, Malcolm R Ranson, Robert Sloane |
| المصدر: | Journal of Clinical Oncology. 29:1556-1563 |
| بيانات النشر: | American Society of Clinical Oncology (ASCO), 2011. |
| سنة النشر: | 2011 |
| مصطلحات موضوعية: | Adult, Male, Oncology, Cancer Research, medicine.medical_specialty, Pathology, Lung Neoplasms, Time Factors, medicine.medical_treatment, Kaplan-Meier Estimate, Risk Assessment, Disease-Free Survival, chemistry.chemical_compound, Circulating tumor cell, Predictive Value of Tests, Risk Factors, Carcinoma, Non-Small-Cell Lung, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, Biomarkers, Tumor, Carcinoma, medicine, Humans, Prospective Studies, Stage (cooking), Lung cancer, Prospective cohort study, Aged, Neoplasm Staging, Proportional Hazards Models, Aged, 80 and over, Chemotherapy, Immunomagnetic Separation, business.industry, Cancer, Epithelial cell adhesion molecule, Middle Aged, Neoplastic Cells, Circulating, medicine.disease, Treatment Outcome, England, chemistry, Female, business, Cell Adhesion Molecules |
| الوصف: | Purpose Lung cancer is the leading cause of cancer-related death worldwide. Non–small-cell lung cancer (NSCLC) lacks validated biomarkers to predict treatment response. This study investigated whether circulating tumor cells (CTCs) are detectable in patients with NSCLC and what their ability might be to provide prognostic information and/or early indication of patient response to conventional therapy. Patients and Methods In this single-center prospective study, blood samples for CTC analysis were obtained from 101 patients with previously untreated, stage III or IV NSCLC both before and after administration of one cycle of standard chemotherapy. CTCs were measured using a semiautomated, epithelial cell adhesion molecule–based immunomagnetic technique. Results The number of CTCs in 7.5 mL of blood was higher in patients with stage IV NSCLC (n = 60; range, 0 to 146) compared with patients with stage IIIB (n = 27; range, 0 to 3) or IIIA disease (n = 14; no CTCs detected). In univariate analysis, progression-free survival was 6.8 v 2.4 months with P < .001, and overall survival (OS) was 8.1 v 4.3 months with P < .001 for patients with fewer than five CTCs compared with five or more CTCs before chemotherapy, respectively. In multivariate analysis, CTC number was the strongest predictor of OS (hazard ratio [HR], 7.92; 95% CI, 2.85 to 22.01; P < .001), and the point estimate of the HR was increased with incorporation of a second CTC sample that was taken after one cycle of chemotherapy (HR, 15.65; 95% CI, 3.63 to 67.53; P < .001). Conclusion CTCs are detectable in patients with stage IV NSCLC and are a novel prognostic factor for this disease. Further validation is warranted before routine clinical application. |
| تدمد: | 1527-7755 0732-183X |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::639e62360c35d35e99965e7ba53d0bd0 https://doi.org/10.1200/jco.2010.28.7045 |
| رقم الأكسشن: | edsair.doi.dedup.....639e62360c35d35e99965e7ba53d0bd0 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 15277755 0732183X |
|---|